Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website

CGTX•2026-07-13

Press release posted for B. Riley summit fireside chat

Cognition Therapeutics posted a new press release announcing CEO Lisa Ricciardi will join a fireside chat at B. Riley’s Mind, Muscle & Vision Summit.

The July 16, 2026 session will cover the ongoing Phase 2 START study, plans to launch a Phase 3 registrational trial of zervimesine (CT1812) in DLB psychosis.

A replay is expected to be available on the company’s investor relations site at https://cogrx.com.

Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website

Press release posted for B. Riley summit fireside chat

Related News

Gloo Holdings announces availability of press release on public offering closing

China aims to spur consumption in first five-year blueprint

Matinas BioPharma agrees to sell Nanotechnologies unit to Azurity for $4 million upfront

OmniAb files initial beneficial ownership statement for COO Amechi Ekeke Nwachuku

Syntec Optics receives new orders for two additional AR defense display windows